How a consultant separates price-led revenue growth from visit volume, prices doctor dependency, and builds a lender-grade projection for SBA, USDA, and conventional veterinary financing — in a sector where practices are billing more while seeing fewer patients.
Growing on price, shrinking on volume
The central fact about veterinary practice in 2026 is that revenue growth and patient volume have decoupled.
Industry survey data through late 2025 shows veterinarians reporting increasing client price sensitivity alongside decreasing visits. As one industry economist summarised it, the profession is still growing revenue, but that growth is increasingly driven by higher prices rather than higher patient volume.
That distinction is the whole analytical problem. A practice growing revenue 6% a year while seeing 3% fewer patients is a different business from one growing 6% on volume, and only one of those trajectories is sustainable — price increases against rising client price sensitivity have a ceiling that visit growth does not.
The same economist has been explicit that he does not anticipate a significant market rebound in 2026, and that he is not seeing the factors that would drive a meaningful turnaround.
What this requires of the consultant: a revenue build that separates visits from average transaction value, projects each independently, and states the assumption underlying continued price realisation. A projection applying a blended growth rate to historical revenue has concealed the sector's defining dynamic.
Doctor count is the business
If one variable explains veterinary practice value and risk, it is the number of practising veterinarians and how dependent the practice is on any one of them.
The transaction market prices this with unusual clarity. Published guidance places solo, owner-dependent practices in a band around 3.5x to 6x adjusted EBITDA, with practices at $200,000 to $500,000 of seller's discretionary earnings trading nearer 5x to 7x EBITDA. Multi-doctor practices at $1 million to $3 million of EBITDA reach roughly 8x to 11.5x, and platform-eligible operators above $3 million reach higher still. Across the full range, practices sell somewhere between roughly 4x and 14x adjusted EBITDA — and doctor count explains most of that spread.
The reason is straightforward. A solo practice's production, client relationships and clinical reputation reside in one person. When that person leaves, the revenue does not automatically remain.
The associate bench is itself the asset. Market observation is that a practice retaining its associates through recent years commands top-of-band pricing, while a practice with a departing associate trades at the bottom of its band — because the buyer models replacement recruitment cost and the downtime before a new doctor reaches production.
What the consultant establishes:
- Production by individual doctor as a share of total revenue
- Whether associates are employed or contracted, and under what terms
- Restrictive covenant enforceability in that state, which varies substantially and determines whether associate production is genuinely transferable
- The seller's transition commitment — duration, capacity, compensation
- Whether the buyer, if an individual veterinarian, can produce at the level the model assumes
Where a solo owner produces the overwhelming majority of revenue and intends to exit within ninety days, that is the credit issue, and it should appear in the study rather than in a lender's later question.
The shortage is both the moat and the constraint
Mars Veterinary Health and the American Association of Veterinary Medical Colleges have jointly projected a shortfall of roughly 15,000 companion animal veterinarians by 2030. Workforce data has documented a structural DVM shortage since around 2020, with consistent wage inflation over the same period.
This cuts two ways, and a good study addresses both.
As a moat, the shortage protects incumbents. A practice that has doctors is difficult to compete against, and corporate groups treat their recruiting and retention capability as a genuine competitive advantage over solo practices.
As a constraint, it is the binding limit on organic growth. Same-store staffing capacity — not client demand — is what caps revenue at many practices. A projection showing revenue growth that implicitly requires an additional doctor must establish that the doctor can be recruited, at what compensation, and how long it takes.
The succession dimension matters too. Median owner-veterinarian age sits well above 55, and consolidators have been actively working that succession window. For an individual buyer, this means supply of practices for sale is reasonable — and also that the seller is frequently the practice's principal producer and its client relationship.
What the consultant actually does
Defines the service area realistically
Companion animal practice draws from a tight catchment — typically ten to twenty minutes drive time for routine care, wider for specialty and emergency. Mixed and large animal practice draws far wider on a different geography entirely, following livestock rather than households.
The two should never be analysed the same way.
Sizes demand from pet population, not human population
The credible chain runs: households in the catchment → pet ownership rate → pets by species → annual visit frequency by species and age → total addressable visits → competing capacity → achievable share.
Visit frequency is where the current softness shows up, and using pre-2024 frequency assumptions overstates demand. The analysis should reflect that clients are deferring discretionary and wellness visits under price pressure.
Maps competitive capacity in doctors, not clinics
A competitor count is not a capacity measure. What matters is the number of practising veterinarians within the catchment, their apparent capacity, whether they are accepting new clients, and whether corporate-owned clinics in the area are operating at, above or below capacity.
Corporate presence should be assessed rather than merely noted. Corporate ownership of general practice clinics has crossed roughly 25% by practice count, and higher by revenue share, with some estimates placing combined corporate and private-equity ownership around half of US clinics. A catchment with a Banfield inside a pet retailer, a VCA general practice and a specialty referral centre is a different competitive environment from one with three independents.
Builds revenue by doctor and by service line
Revenue = doctors × clinical days × visits per day × average transaction value, with average transaction value built from service mix rather than assumed.
Service lines carry different economics and different trajectories:
- Wellness and preventive care, increasingly sold through subscription wellness plans that produce recurring revenue and improve retention
- Sick visits and diagnostics, where imaging and in-house laboratory capability drive both revenue and margin
- Surgery and dentistry, higher value and capacity-constrained
- Pharmacy and retail, which requires specific attention below
- Boarding, grooming and ancillary, where offered
Treats pharmacy erosion as structural
Online pet pharmacy and direct-to-consumer retail have compressed the pharmacy attach economics that historically supported practice margin. This is a slow structural drag rather than a shock, but it runs in one direction.
A projection carrying historical pharmacy margin forward unadjusted is overstating revenue, and the analysis should either model continued erosion or explain why the subject is insulated — for example through practice-linked online dispensing that retains the margin.
Models the cost structure
- Doctor compensation is typically production-based and therefore substantially variable, but with a floor. DVM wage inflation has been persistent and should not be modelled flat.
- Support staffing — technicians, assistants, client service — where technician shortage and turnover mirror the DVM problem at lower wage levels.
- Drugs, supplies and laboratory, scaling with visit volume and service mix.
- Occupancy at contracted rent with escalations, or debt service where the property is owned.
- Equipment finance for imaging, dental, anaesthesia and laboratory equipment, which is substantial in a modern practice.
- Insurance, including professional liability.
- Marketing, which is not optional in a practice transitioning ownership.
- Replacement reserves. Digital radiography, ultrasound, anaesthesia machines, dental equipment, laboratory analysers and practice management systems all have finite lives and meaningful replacement costs. Where financing is USDA-guaranteed this is a regulatory requirement, since 7 CFR Part 5001 defines coverage as EBITDA less reasonably expected replacement capital expenditures.
The transaction context an SBA buyer is entering
For an individual veterinarian buying a practice, the current market has a specific shape worth understanding.
Consolidation has cooled from its peak. Practice acquisition volume and valuations have both declined as higher rates made debt-funded deals more expensive and pressured corporate group margins. The 2021 high-water mark saw values reaching the equivalent of 18 to 20 times earnings in some cases; that is not the current market. Some private-equity-backed groups are under pressure to recapitalise or exit, and at least one major platform has been rated deep in speculative territory.
Well-performing practices still attract strong demand, and consolidators remain active on larger, multi-doctor assets — that is where scale economics work for them.
The practical consequence for an individual buyer is that the solo and small practice segment, which corporate buyers find less attractive, is where SBA-financed buyers compete most effectively. That is also the segment with the highest owner dependency, which is precisely the risk the feasibility study has to address.
Regulatory change is worth monitoring. Several states have introduced legislation tightening corporate practice of medicine rules and limiting certain management services organisation structures used in veterinary consolidation. This affects the competitive landscape and, in some cases, exit optionality.
Sensitivity that matters here
- Doctor departure. Coverage if the primary producing associate leaves in year two, including recruitment cost and production downtime.
- Visit volume. Coverage at 90% and 85% of projected visits, reflecting the sector's current volume softness.
- Price realisation. What happens if average transaction value growth stalls against client price resistance.
- Recruitment failure. Where growth requires an additional doctor, coverage if that position remains unfilled.
- Pharmacy erosion, at an accelerated rate.
How the programmes differ
SBA 7(a). The dominant route for individual veterinarian buyers acquiring single practices. SOP 50 10 8 sets when a third-party study is expected, and a change of ownership — the typical structure here — falls within it.
SBA 504. Where the transaction includes real estate. Practice real estate is frequently owned by the selling veterinarian and offered alongside the practice, and a combined structure is common enough to be worth evaluating at the outset.
USDA B&I. Available in communities of 50,000 or fewer, up to $25 million, with fiscal 2026 guarantees at 85% below $5 million and 80% at or above. Rural veterinary practice deserves specific mention: mixed and large animal practice serves agricultural producers, veterinary shortage in rural areas is acute, and the community and economic impact argument USDA weighs is genuinely strong rather than stretched. Rural practices also face thinner competition and larger catchments, with correspondingly greater exposure to a single doctor.
Conventional. Specialist practice lenders understand doctor dependency, production splits and transition risk without prompting, and will test them.
In all cases the study must be prepared by an independent third party with no financial interest in the transaction.
What the lender is reading for
- How many doctors, and who produces what? The first question, and in a solo acquisition frequently the whole question.
- Is revenue growth priced or volumed? A projection that does not separate them has not engaged with the sector.
- Can the practice recruit if it needs to? Given a projected national shortfall of roughly 15,000 companion animal veterinarians by 2030, growth assumptions requiring additional doctors need support.
- Does the buyer have the production capacity assumed? Particularly where an associate or first-time owner is stepping into a founder's book.
- What happens to the client base on transition?
Veterinary practice remains a fundamentally attractive credit — demand is durable, care is increasingly non-discretionary in the eyes of owners, and the shortage protects incumbents. But visits are down, price sensitivity is up, consolidators have retreated from the frenzy that once set valuations, and the value of a practice sits substantially in people who can leave. A consultant's job here is to make the doctor dependency explicit and to price it, rather than describing pet ownership trends and calling it demand analysis.
Prepared by feasibility-study-consultant.com. Market data reflects published sources at the date of writing and moves with transaction conditions. Corporate practice of medicine rules and restrictive covenant enforceability vary by state. Programme requirements should be verified against current SBA and USDA guidance. Last updated: July 30, 2026.